Kymera Therapeutics

Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors

Data will be shared in an oral presentation at the 2019 American College of Rheumatology’s Annual Meeting in Atlanta Cambridge, Mass. (November 11, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients,